In this phase 3 , randomised , double-blind , placebo-controlled field trial , healthy adults ( aged 18-64 years ) travelling from Germany or the UK to Mexico or Guatemala were assigned in a 1:1 ratio by a dynamic electronic randomisation system to receive transcutaneous immunisation with a patch containing 37.5 g of ETEC LT or a placebo patch .